CSIMarket Company Name, Ticker, Suppliers, else..
 
Xoma Royalty Corporation  (NASDAQ: XOMA)
 
Price: $40.1700 $40.17 %
Day's High: $40.16999816894531 Week Perf: 0.00
Day's Low: $ 40.17 30 Day Perf: -4.11 %
Volume (M): 0 52 Wk High: $ 45.22
Volume (M$): $ 0 52 Wk Avg: $34.03
Open: $40.17 52 Wk Low: $22.29



 Market Capitalization (Millions $) 700
 Shares Outstanding (Millions) 17
 Employees 14
 Revenues (TTM) (Millions $) 49
 Net Income (TTM) (Millions $) 20
 Cash Flow (TTM) (Millions $) 44
 Capital Exp. (TTM) (Millions $) 21

Business Description


Xoma Corporation is a biotechnology company that specializes in the research, development, and commercialization of therapeutic antibodies and other technologies for the treatment of various diseases. The company focuses on developing antibody-based therapies for inflammatory and autoimmune disorders, as well as for cancer and infectious diseases. Xoma has a robust pipeline of product candidates and utilizes its proprietary antibody discovery and optimization technologies to advance its research and development efforts. The company aims to bring innovative treatments to patients and improve clinical outcomes across a wide range of medical conditions.


   Company Address: 2200 Powell Street Emeryville 94608 CA
   Company Phone Number: 204-7200   Stock Exchange / Ticker: NASDAQ XOMA


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
ABBV   -3.49%    
BMY   -3.75%    
JNJ   -1.52%    
LLY   -3.09%    
MRK   -1.55%    
PFE   -2.7%    
• View Complete Report
   



Contract

XOMA Royalty Reports Remarkable Sales Surge Amid Kinnate Asset Divestiture and Competitive Revenue Landscape

Published Mon, Apr 14 2025 11:52 AM UTC

In a dynamic landscape dominated by relentless competition, XOMA Royalty Corporation has made notable strides with the recent divestiture of its remaining Kinnate pipeline assets. This strategic move has potentially transformative implications for the company, with total proceeds from the sale reaching as high as $270 million. The deal encompasses not only upfront and milest...
Merger and Acquisition

XOMA Royalty Expands Its Pipeline with Seralutinib, Securing $8.1 Million Milestone Payment Despite Stock Challenges,

Published Mon, Dec 2 2024 12:30 PM UTC

XOMA Royalty Expands Its Portfolio with Seralutinib, Secures Milestone Payment Amid Market ChallengesIn a significant move that underscores its commitment to shareholders, XOMA Corporation (NASDAQ: XOMA) has added Seralutinib as its seventh Phase 3 royalty asset, further solidifying its pipeline of late-stage therapeutics. Announced on June 12, 2024, this development bolster...
Management Announcement

XOMA Corporation Demonstrates Commitment to Shareholders and Receives $8.1 Million Milestone Payment Amidst Challenging Stock Performance

Published Wed, Jun 12 2024 11:30 AM UTC

XOMA s Cash Infusion and Commitment to Shareholders Amidst Stock Performance Challenges
EMERYVILLE, Calif., June 12, 2024 - XOMA Corporation (NASDAQ: XOMA), a biotech royalty aggregator, recently received an $8.1 million milestone payment from Viracta Therapeutics, Inc., following the sale of Day One Biopharmaceuticals Priority Review Voucher (PRV) for $108 million to...
Announcement

XOMA celebrates $9 Million Milestone from Q1 2024 Financial Results; FDA Approves Day One's OJEMDA

Published Thu, May 9 2024 11:30 AM UTC

In the f...
Product Service News

XOMA's Innovative Royalty Portfolio Expands with First-in-Category Assets Including XACIATO (clindamycin phosphate) Vaginal Gel 2%

Published Tue, Apr 30 2024 11:30 AM UTC

CSIMarket.com XOMA, a leading biotechnology company, has recently announced the addition of three first-in-category assets to its existing royalty and milestone portfolio. These assets encompass cutting-edge pharmaceutical products, among which is XACIATO (clindamycin phosphate) Vaginal Gel 2%. This article aims to provide an unbiased assessment of this development based on...



Fundamental Analysis

Valuation Current
Price to Earnings PE Ratio (TTM) 26.96
Price to Earnings PE Ratio (Expected) -
Price to Sales (TTM) 14.41
Price to Sales (Expected) -
Price to Book 7.53
PEG (TTM) -

Financial Strength Current
Quick Ratio 2.59
Working Capital Ratio 3.59
Leverage Ratio (MRQ) 1.93
Total Debt to Equity 1.11
Interest Coverage (TTM) 4.11
Debt Coverage (TTM) 0.49

Per Share Current
Earnings (TTM) 1.49 $
Revenues (TTM) 2.79 $
Cash Flow (TTM) 2.51 $
Cash 4.91 $
Book Value 5.33 $
Dividend (TTM) 0.34 $

Efficiency Current
Revenue per Employee (TTM) 3,468,214
Net Income per Employee (TTM) 1,423,714
Receivable Turnover Ratio (TTM) 13.05
Inventory Turnover Ratio (TTM) -
Asset Turnover Ratio (TTM) 0.19

Profitability Ratios Current
Gross Margin (MRQ) -
Operating Margin (MRQ) -3.9 %
Net Margin (MRQ) 17.22 %
Net Cash Flow Margin (MRQ) 40.86 %
Effective Tax Rate (TTM) 0.29 %

Management Effectiveness Current
Return On Assets (TTM) 7.73 %
Return On Investment (TTM) 8.73 %
Return On Equity (TTM) 23.64 %
Dividend Yield 0.82 %
Pay out Ratio (TTM) 22.82 %



Xoma Royalty's Segments
Single Reportable Segment    100 % of total Revenue
United States    45.64 % of total Revenue
Switzerland    54.36 % of total Revenue





Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.